Thaci, D., Strober, B., Gordon, K., Foley, P., Gooderham, M., Morita, A., . . . Gottlieb, A. (2022). Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.
Citación estilo ChicagoThaci, D., et al. Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial. 2022.
Cita MLAThaci, D., et al. Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial. 2022.
Precaución: Estas citas no son 100% exactas.